Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
IPO Year:
Exchange: NASDAQ
Website: inotivco.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2024 | $11.50 → $3.75 | Buy → Hold | Jefferies |
| 2/9/2024 | $3.00 → $11.50 | Hold → Buy | Jefferies |
| 7/20/2023 | $9.00 | Overweight | Wells Fargo |
| 1/19/2023 | $10.00 → $8.00 | Buy → Hold | Jefferies |
| 1/11/2023 | $4.00 → $10.00 | Hold → Buy | Lake Street |
| 11/18/2022 | $60.00 → $7.00 | Buy → Hold | Lake Street |
| 10/4/2022 | $27.00 | Buy | Jefferies |
| 1/31/2022 | $60.00 | Buy | Lake Street |
| 9/20/2021 | $45.00 | Buy | Craig Hallum |
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
EFFECT - Inotiv, Inc. (0000720154) (Filer)
S-3 - Inotiv, Inc. (0000720154) (Filer)
8-K - Inotiv, Inc. (0000720154) (Filer)
8-K - Inotiv, Inc. (0000720154) (Filer)
424B5 - Inotiv, Inc. (0000720154) (Filer)
10-Q - Inotiv, Inc. (0000720154) (Filer)
8-K - Inotiv, Inc. (0000720154) (Filer)
8-K - Inotiv, Inc. (0000720154) (Filer)
S-8 POS - Inotiv, Inc. (0000720154) (Filer)
S-8 POS - Inotiv, Inc. (0000720154) (Filer)
WEST LAFAYETTE, Ind., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Inotiv today announced it ranked 138 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. Over the last five years Inotiv grew 847%. Inotiv's president and chief executive officer, Robert Leasure, Jr., credits the company's growth trajectory to listening to customers' concerns and needs. He said, "Inotiv is incredibly proud to be recognized as a 2024 Deloitte Technology Fast 500™ winner for a second year. As we continue to build a top-tier, mid-sized, full-service CRO and provider of research models, we
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-267-6316 (Domestic)1-203-518-9783 (In
WEST LAFAYETTE, Ind., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, will present at the upcoming Jefferies London Global Healthcare Conference. Beth Taylor, Chief Financial Officer, will participate at the upcoming 15th Annual Craig-Hallum Alpha Select Conference. Conference Details Jefferies 2024 London Global Healthcare ConferencePresenter: Robert Leasure Jr., President and Chief Executiv
WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has amended certain terms of its Credit Agreement. In addition, Inotiv has closed the sale of $22.6 million aggregate principal amount of 15% Senior Secured Second Lien PIK Notes due February 2027 (the "Second Lien Notes"), and warrants to purchase common shares, to certain investors in a private offering. Robert Leasure Jr., President and Chief Executive Officer, commented, "In order to increase our l
WEST LAFAYETTE, Ind., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., Inotiv's President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the 8th Annual Lake Street Best Ideas Growth Conference on Thursday, September 12, 2024, in New York City. Management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact the
— Third quarter fiscal 2024 revenue down 32.8% to $105.8 million — Year-to-date fiscal 2024 revenue down 16.5% to $360.3 million — Conclusion of certain government investigations — Site optimization projects complete — Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q3 FY 2024") and nine months ("YTD FY 2024") ended June 30, 2024. Revenue by Segment (in millions
WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, on Thursday, August 8, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-225-9448 (Domestic)1-203-518-9708 (International)
WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates: Hillcrest, U.K. expansion project completedExtension of the maturity date of the $3.7 million OBRC payable note to July 2025 Robert Leasure Jr., President and Chief Executive Officer, commented, "We have substantially completed the Hillcrest, U.K. expansion and improvements, which allows for two new customers with long term contracts, to begin occupyin
WEST LAFAYETTE, Ind., June 03, 2024 (GLOBE NEWSWIRE) -- Inotiv Inc. – Inotiv Inc. ("Inotiv" or the "Company") (NASDAQ:NOTV), a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models, today announced that it reached an agreement with the U.S. Department of Justice ("DOJ") to resolve a previously-announced criminal investigation into the shuttered canine breeding facility located in Cumberland, Virginia, which was operated originally by Envigo RMS LLC ("Envigo"), a company acquired by Inotiv in November 2021. Before the United States District Court for the Western District of Virginia, Envigo RMS pl
WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming 21st Annual Craig Hallum Institutional Investor Conference and Jefferies Global Healthcare Conference. Conference DetailsEvent: 21st Annual Craig Hallum Institutional Investor ConferenceLocation: Minneapolis, MNDate: May 29, 2024Event format: 1-on-1 institutional
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SC 13G/A - Inotiv, Inc. (0000720154) (Subject)
SC 13G/A - Inotiv, Inc. (0000720154) (Subject)
SC 13G/A - Inotiv, Inc. (0000720154) (Subject)
SC 13D - Inotiv, Inc. (0000720154) (Subject)
SC 13D - Inotiv, Inc. (0000720154) (Subject)
SC 13G - Inotiv, Inc. (0000720154) (Subject)
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-267-6316 (Domestic)1-203-518-9783 (In
— Third quarter fiscal 2024 revenue down 32.8% to $105.8 million — Year-to-date fiscal 2024 revenue down 16.5% to $360.3 million — Conclusion of certain government investigations — Site optimization projects complete — Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q3 FY 2024") and nine months ("YTD FY 2024") ended June 30, 2024. Revenue by Segment (in millions
WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, on Thursday, August 8, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-225-9448 (Domestic)1-203-518-9708 (International)
— Second quarter fiscal 2024 revenue down 21.5% to $119.0 million— Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million— Agreement in principle reached with the U.S. Department of Justice on related matter— Site optimization projects near completion— Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q2 FY 2024") and six months ("YTD FY 2024") ended March 31,
WEST LAFAYETTE, Ind., May 14, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, on Wednesday, May 15, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: (888) 886-7786 (Domestic)(416) 764-8658 (International)38070700
WEST LAFAYETTE, Ind., May 09, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the release of the Company's financial results for the three and six months ended March 31, 2024 and the conference call to discuss the results that were originally scheduled for Friday, May 10, 2024 are being rescheduled to provide the Company additional time to complete the accounting analyses related to certain matters. Specifically, as previously disclosed, the Company has been cooperating wi
WEST LAFAYETTE, Ind., April 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, on Friday, May 10, 2024, before the opening of the stock market. The Company will host a conference call that same day at 8:30 a.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: (888) 886-7786 (Domestic)(416) 764-8658 (International)380707
- First quarter fiscal 2024 revenue up 10.3% to $135.5 million - First quarter fiscal 2024 DSA revenue up 8.8% to $44.7 million and RMS revenue up 11.1% to $90.8 million - Shift to a renewed focus on sales and marketing as near-term infrastructure projects near completion - Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2024") ended December 31, 2023.
WEST LAFAYETTE, Ind., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, on Wednesday, February 7, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: (877) 704-4453 (Domestic)(201) 389-0920 (International)1
— Fiscal year 2023 revenue up 4.5% to $572.4 million, achieving full year revised guidance— Achievements in the past fiscal year to expand DSA capacity, develop new services and reduce outsourcing expected to drive continued growth of fiscal 2024 DSA revenues— Anticipate achieving the balance of expected expense reductions in fiscal 2024— Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results
Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti
WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board's succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board. Ms. Coelho is the CFO at Gamida Cell Ltd., a public, commercial stage biotech company. Previously, Ms. Coelho was Executive Vice President, CFO and Chief Business Development Offic
Jefferies downgraded Inotiv from Buy to Hold and set a new price target of $3.75 from $11.50 previously
Jefferies upgraded Inotiv from Hold to Buy and set a new price target of $11.50 from $3.00 previously
Wells Fargo initiated coverage of Inotiv with a rating of Overweight and set a new price target of $9.00
Jefferies downgraded Inotiv from Buy to Hold and set a new price target of $8.00 from $10.00 previously
Lake Street upgraded Inotiv from Hold to Buy and set a new price target of $10.00 from $4.00 previously
Lake Street downgraded Inotiv from Buy to Hold and set a new price target of $7.00 from $60.00 previously
Jefferies initiated coverage of Inotiv with a rating of Buy and set a new price target of $27.00
Lake Street initiated coverage of Inotiv with a rating of Buy and set a new price target of $60.00
Craig Hallum initiated coverage of Inotiv with a rating of Buy and set a new price target of $45.00
Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates: Hillcrest, U.K. expansion project completed Extension of the maturity date of the $3.7 million OBRC payable note to July 2025 Robert Leasure Jr., President and Chief Executive Officer, commented, "We have substantially completed the Hillcrest, U.K. expansion and improvements, which allows for two new customers with long term contracts, to begin occupying their new space at this facility and for the transfer
Gainers FibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million. Candel Therapeutics (NASDAQ:CADL) stock increased by 8.12% to $9.05. The company's market cap stands at $269.2 million. RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 7.53% to $4.28. The market value of their outstanding shares is at $149.3 million. Gritstone Bio (NASDAQ:GRTS) shares increased by 7.24% to $0.79. The market value of their outstanding shares is at $85.4 million. Scholar Rock Holding (NASDAQ:SRRK) shares rose 6.96% to $10.14. The company's market cap stands at $808.7 million. Novo Integrated
- Reuters
Gainers Larimar Therapeutics (NASDAQ:LRMR) stock increased by 23.6% to $8.99 during Monday's after-market session. The company's market cap stands at $573.5 million. GT Biopharma (NASDAQ:GTBP) stock rose 6.53% to $8.31. The company's market cap stands at $11.4 million. As per the press release, Q1 earnings came out 3 days ago. DermTech (NASDAQ:DMTK) shares moved upwards by 5.52% to $0.38. The market value of their outstanding shares is at $13.2 million. As per the news, the Q1 earnings report came out 4 days ago. BiomX (AMEX:PHGE) shares rose 5.38% to $0.36. The company's market cap stands at $19.8 million. Sharecare (NASDAQ:SHCR) shares rose 4.99% to $0.88. The market value of their ou
Lake Street analyst Frank Takkinen downgrades Inotiv (NASDAQ:NOTV) from Buy to Hold and lowers the price target from $10 to $2.
Craig-Hallum analyst Matt Hewitt maintains Inotiv (NASDAQ:NOTV) with a Buy and lowers the price target from $25 to $10.
Inotiv (NASDAQ:NOTV) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.54) by 53.7 percent. The company reported quarterly sales of $119.035 million which missed the analyst consensus estimate of $129.778 million by 8.28 percent. This is a 21.41 percent decrease over sales of $151.463 million the same period last year.
Gainers SINTX Techs (NASDAQ:SINT) shares increased by 22.2% to $0.16 during Wednesday's after-market session. The company's market cap stands at $19.1 million. As per the news, the Q1 earnings report came out 2 days ago. Petros Pharma (NASDAQ:PTPI) shares rose 12.85% to $0.58. The market value of their outstanding shares is at $4.0 million. Bluejay Diagnostics (NASDAQ:BJDX) shares increased by 10.22% to $0.58. The market value of their outstanding shares is at $1.5 million. INVO Bioscience (NASDAQ:INVO) stock rose 7.47% to $1.15. The market value of their outstanding shares is at $4.3 million. Scorpius Holdings (AMEX:SCPX) shares moved upwards by 7.2% to $0.08. The market value of their
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.22% to 39,519.75 while the NASDAQ rose 0.64% to 16,492.50. The S&P 500 also rose, gaining, 0.34% to 5,239.17. Check This Out: Top 5 Tech And Telecom Stocks Which Could Rescue Your Portfolio This Quarter Leading and Lagging SectorsReal estate shares rose by 0.5% on Tuesday. In trading on Tuesday, energy shares fell by 0.7%. Top Headline Alibaba Group Holding Limited (NYSE:BABA) reported weaker-than-expected earnings for its fiscal fourth-quarter. The e-commerce giant reported fiscal fourth-quarter 2023 revenue growth of 7% year-on-ye